Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors

Antoinette R. Tan(Rutgers Cancer Institute of New Jersey), Darlene Gibbon(Cancer Institute of Florida), Mark N. Stein(Cancer Institute of Florida), Diana Lindquist(Rutgers Cancer Institute of New Jersey), Jeffery W. Edenfield(Translational Research in Oncology), Julie Martin(Translational Research in Oncology), Charles Gregory(Translational Research in Oncology), A. Benjamin Suttle(GlaxoSmithKline (Netherlands)), Hiroomi Tada(GlaxoSmithKline (Netherlands)), Jeffrey Botbyl, Joseph J. Stephenson(Translational Research in Oncology)
Cancer Chemotherapy and Pharmacology
April 30, 2013
10.1007/s00280-013-2164-3
Cited by 106

Abstract

Related Papers

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg, Ian D. Davis, Jozef Mardiak et al.|Journal of Clinical Oncology|2010|2.5k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla et al.|The Lancet|2012|2.1k
THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE
Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf et al.|Drug Metabolism and Disposition|2003|784
Gastric Acid Control With Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, and Rabeprazole: A Five-Way Crossover Study
Philip B. Miner, Philip O. Katz, Yusong Chen et al.|The American Journal of Gastroenterology|2003|433
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole
Klaus T. Olkkola, Janne T. Backman, Pertti J. Neuvonen|Clinical Pharmacology & Therapeutics|1994|412